Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;38(5):854-865.
doi: 10.1002/mds.29349. Epub 2023 Feb 14.

Statin Use and Incidence of Parkinson's Disease in Women from the French E3N Cohort Study

Thi Thu Ha Nguyen  1 , Agnès Fournier  1 , Émeline Courtois  2 , Fanny Artaud  1 , Sylvie Escolano  2 , Pascale Tubert-Bitter  2 , Marie-Christine Boutron-Ruault  1 , Isabelle Degaey  1 , Emmanuel Roze  3   4 , Marianne Canonico  1 , Ismaïl Ahmed  2 , Anne C M Thiébaut  2 , Alexis Elbaz  1
Affiliations

Statin Use and Incidence of Parkinson's Disease in Women from the French E3N Cohort Study

Thi Thu Ha Nguyen et al. Mov Disord. 2023 May.

Abstract

Background: Statins represent candidates for drug repurposing in Parkinson's disease (PD). Few studies examined the role of reverse causation, statin subgroups, and dose-response relations based on time-varying exposures.

Objectives: We examined whether statin use is associated with PD incidence while attempting to overcome the limitations described previously, especially reverse causation.

Method: We used data from the E3N cohort study of French women (follow-up, 2004-2018). Incident PD was ascertained using multiple sources and validated by experts. New statin users were identified through linked drug claims. We set up a nested case-control study to describe trajectories of statin prescriptions and medical consultations before diagnosis. We used time-varying multivariable Cox proportional hazards regression models to examine the statins-PD association. Exposure indexes included ever use, cumulative duration/dose, and mean daily dose and were lagged by 5 years to address reverse causation.

Results: The case-control study (693 cases, 13,784 controls) showed differences in case-control trajectories, with changes in the 5 years before diagnosis in cases. Of 73,925 women (aged 54-79 years), 524 developed PD and 11,552 started using statins in lagged analyses. Ever use of any statin was not associated with PD (hazard ratio [HR] = 0.87, 95% confidence interval [CI] = 0.67-1.11). Alternatively, ever use of lipophilic statins was significantly associated with lower PD incidence (HR = 0.70, 95% CI = 0.51-0.98), with a dose-response relation for the mean daily dose (P-linear trend = 0.02). There was no association for hydrophilic statins.

Conclusion: Use of lipophilic statins at least 5 years earlier was associated with reduced PD incidence in women, with a dose-response relation for the mean daily dose. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; cohort studies; drug repurposing; pharmacoepidemiology; statins.

PubMed Disclaimer

References

    1. Berg D, Crotty GF, Keavney JL, Schwarzschild MA, Simuni T, Tanner C. Path to Parkinson disease prevention: conclusion and outlook. Neurology 2022;99:76-83.
    1. Undela K, Gudala K, Malla S, Bansal D. Statin use and risk of Parkinson's disease: a meta-analysis of observational studies. J Neurol 2013;260:158-165.
    1. Bai S, Song Y, Huang X, et al. Statin use and the risk of Parkinson's disease: an updated meta-analysis. PLoS One 2016;11:e0152564.
    1. Sheng Z, Jia X, Kang M. Statin use and risk of Parkinson's disease: a meta-analysis. Behav Brain Res 2016;309:29-34.
    1. Bykov K, Yoshida K, Weisskopf MG, Gagne JJ. Confounding of the association between statins and Parkinson disease: systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2017;26:294-300.

Publication types

Substances

LinkOut - more resources